Retroperitoneal Approach Highlights the Advantages of Single-Port Surgery

Seoul St. Mary's Hospital announced on August 4 that Professor Sung-Hoo Hong of the Department of Urology has become the first in the Asia-Pacific region to personally achieve 1,000 cases of single-port (SP) urologic robotic surgeries.

Professor Sunghoo Hong of the Department of Urology at Seoul St. Mary's Hospital achieved a personal milestone of 1,000 single-port (SP) urologic robot surgeries for the first time in the Asia-Pacific region on August 3, and is taking a commemorative photo with the medical staff. Seoul St. Mary's Hospital

Professor Sunghoo Hong of the Department of Urology at Seoul St. Mary's Hospital achieved a personal milestone of 1,000 single-port (SP) urologic robot surgeries for the first time in the Asia-Pacific region on August 3, and is taking a commemorative photo with the medical staff. Seoul St. Mary's Hospital

View original image

Of the total surgeries, 97% were performed on urologic cancer patients, with kidney cancer accounting for the largest proportion at 54%. Notably, partial nephrectomy procedures, which preserve renal function by excising only the tumor area, made up more than half of the cases, totaling 539 surgeries.


Professor Hong overcame the traditionally cited weakness of single-port robotic surgery—its slower surgical speed—through surgical technique improvements. In a study on kidney cancer patients, the average warm ischemia time for single-port surgery was 13.8 minutes, which is 19.8% shorter than the 17.2 minutes for multi-port surgery. The average operative time was also shorter, at 95.4 minutes for single-port surgery compared to 103.7 minutes for multi-port surgery.


Professor Hong has led the development of surgical techniques in the field of single-port robotic surgery, performing Korea's first Retzius-sparing prostatectomy using a single-port robot and demonstrating the effectiveness of retroperitoneal approaches for kidney cancer surgeries. More recently, he became the first in Korea and the second in the world to successfully treat an elderly patient with renal cell carcinoma and inferior vena cava thrombus using single-port robotic surgery.



Professor Hong stated, "I will continue research aimed at developing and clinically applying treatment methods for malignant diseases such as kidney cancer and prostate cancer."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing